Fig 1.
Screening flowchart for atezolizumab AE reports.
Table 1.
Two-by-two contingency table for disproportionality analysis.
Table 2.
Formulas and thresholds for the MHRA methods.
Table 3.
Demographic information of atezolizumab AE reports.
Fig 2.
Trends in the number of AE reports for atezolizumab (2016 Q2--2024 Q2).
Fig 3.
Gender distribution of AE reporting indications.
Table 4.
The 20 most frequently reported PTs detected by both FAERS and JADER.
Table 5.
PTs determined to be positive signals only in JADER.
Fig 4.
Distribution of AE signals in response to atezolizumab.
Fig 5.
Top 30 AEs with the highest percentage of signal detection in the FAERS (PT = Preferred Term, PRR = Proportional Reporting Ratio, ROR = Reporting Odds Ratio, IC = Information Component).
Fig 6.
Atezolizumab AE reports involving SOCs.
* Indicates SOC not mentioned in the drug instructions.
Fig 7.
Top 50 AEs in terms of IC (PT = Preferred Term, SOC = System Organ Class, PRR = Proportional Reporting Ratio, ROR = Reporting Odds Ratio, IC = Information Component).
* Indicates PT not mentioned in the drug instructions.
Fig 8.
SOC distribution network plot of the top 50 atezolizumab AEs.
Fig 9.
SOC cumulative occurrence time of the top 100 atezolizumab AEs.